Issue Date: May 21, 2007
Dow Licenses Protein Expression ...
Dowpharma has signed two licensing deals for Pfenex, its Pseudomonas-based protein expression technology. India's Biovel Life Sciences will use the technology, as well as a high-yield strain and process developed by Dow, in the production of human growth hormone under a licensing agreement entailing up-front payments as well as milestone and royalty payments. Dow has also licensed Pfenex to VGX Pharmaceuticals for the production of a protein-based cancer therapy.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society